Drug intelligence / Profile preview

4-methylaminorex

Development stage
Unknown
Lead developer
Johnson & Johnson
Modality
Small Molecules
Administration
Oral, Intranasal, Inhalation, Intravenous
01

Overview

**4-methylaminorex** is a synthetic stimulant drug of the 2-amino-5-aryloxazoline class, first synthesized in 1960 by McNeil Laboratories as a potential appetite suppressant. It acts primarily as an indirect sympathomimetic agent, stimulating the release of dopamine and norepinephrine, and to a lesser extent serotonin, by interacting with monoamine transporters. This results in increased alertness, euphoria, cognitive enhancement, and reinforcing properties similar to amphetamines and cocaine but with a longer duration of action. The drug exists as four stereoisomers (cis and trans forms), with varying potency; the trans-(4S,5S) isomer is most potent. Although initially investigated for medical use (notably appetite suppression), its development was discontinued in favor of aminorex due to safety concerns. Today it is classified as a Schedule I substance in many countries due to its abuse potential[1][6][7].

Brand names
U4EuhU-4EuhU 4EuhEuphoriaICEIntellex
Other names
4MA
02

Targets

NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on 4-methylaminorex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-methylaminorex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call